Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

OxyContin sales put Purdue's Sackler family on Forbes rich list

The Busches, the Mellons, the Rockefellers--they're some of America's richest families. But one blockbuster pain drug has put a family of pharma-founders ahead of them all in the wealth department.

Takeda's Hasegawa out as JPMA VP after firm called to task on Blopress

Takeda Pharmaceutical Chairman Yasuchika Hasegawa was removed as vice president by the Japan Pharmaceutical Manufacturers Association, according to an updated leadership list that was confirmed by a company spokesman.

Nathalie Adda named Enanta CMO

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

Viehbacher returns to lead Swiss billionaire's $2B biotech fund

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

Allergan CEO: 'The cuts are done' at layoffs-plagued Irvine campus

The good news for Allergan's ex-headquarters in Irvine, CA: CEO Brent Saunders says the operations there are still key to the company. More good news: The layoffs that hit that site are now over and done, he says.

UPDATED: Bristol-Myers rips up its R&D group, adding, eliminating and moving 800-plus

Bristol-Myers Squibb's R&D organization is being revamped in a major shakeup that will see a new research center open in Cambridge, MA, two other research centers close, with hundreds of jobs being relocated in Massachusetts and Connecticut while about 100 researchers are axed as the Big Biotech shutters its discovery work in virology.

Vectura poaches key AZ respiratory exec to replace departing CEO

What's in the water at AstraZeneca? Maybe it's an elixir for top managers who want to run a smaller drugmaker. Maybe it's an anti-Big Pharma potion. Either way, it means a second high-level exec has left the U.K.-based drugmaker for a CEO post elsewhere.

Pharma in India shakes up executive ranks at Ranbaxy, Cipla, others

A slew of senior executives at the Ranbaxy unit of India's Sun Pharmaceutical and Cipla are likely polishing up their Linkedin profiles and calling head hunters as something of a cull sweeps through management ranks at those companies and wider, highlighting deep changes in the industry.

Ex-AstraZeneca R&D chief Morrison takes helm of Syndax Pharmaceuticals

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

Zoetis to cut 165 workers from NJ headquarters as downsizing gets underway

One month after cutting its sales estimates for this year and announcing a major cost-cutting plan, Zoetis is pulling out the pink sheets at its global headquarters in Florham Park, NJ. The company plans to cut 165 jobs there, according to a notice filed with the state. The cuts will be made by the end of 2016.